Merck to End Development of Two Cancer Candidates: Time to Sell?
Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab. Merck was separately studying vibostolimab and favezelimab in fixed-dose combinations with its blockbuster cancer drug,
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA reviews RSV drug clesrovimab.
Merck discontinues clinical development programs for vibostolimab, favezelimab
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody,
Merck Ends Development of Two Experimental Cancer Drugs
Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively. Merck’s decision followed a series of setbacks for both drugs,
Merck Axes Two Cancer Candidates After Disappointing Late-Stage Results
Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage failures.
Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials
Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an
pharmaphorum1d
End of the line for MSD's TIGIT, LAG-3 cancer drugs
One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
FierceBiotech2d
Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...
The Pharma Letter11h
Merck & Co cuts TIGIT and LAG-3 programs
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Pharmabiz15h
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC
Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...